What does SLEDAI-2K stand for?

Systemic Lupus Erythematosus Disease Activity Index, 2000 revision. It's a validated composite score used to quantify lupus disease activity based on 24 weighted clinical and laboratory descriptors present within the prior 10 days.

What is a normal or good SLEDAI-2K score?

A score of 0 indicates no measurable disease activity by SLEDAI-2K criteria. Scores of 1-5 are considered mild activity. There's no single 'good' score for every patient — the trend over time and which specific descriptors are driving the score matter as much as the absolute number.

What score indicates a lupus flare?

Using the SELENA-SLEDAI flare index, an increase of 3 or more points from the prior visit is classified as a mild/moderate flare, and an increase of 12 or more points (or new appearance of a severe descriptor like nephritis or CNS lupus) is a severe flare.

What's the difference between SLEDAI and SLEDAI-2K?

The 2000 revision (SLEDAI-2K) allows persistent, not just new or worsening, proteinuria, rash, and alopecia to be scored as present, better capturing ongoing chronic disease activity compared to the original 1992 SLEDAI, which only counted new or recurrent findings for those three descriptors.

Does SLEDAI-2K measure organ damage?

No. SLEDAI-2K measures current, potentially reversible disease activity, not cumulative or permanent organ damage. The SLICC/ACR Damage Index is the separate, complementary tool used to track irreversible damage from lupus or its treatment.

Can SLEDAI-2K be used to diagnose lupus?

No. SLEDAI-2K is a disease activity monitoring tool for patients with an established SLE diagnosis, not a diagnostic or classification instrument. Diagnosis relies on separate classification criteria (ACR 1997, SLICC 2012, or EULAR/ACR 2019).

Why is fever only weighted 1 point?

Fever is a low-specificity finding in lupus — it's common in infection, malignancy, and many other conditions unrelated to lupus activity, so it contributes the smallest weight to the composite score, and the descriptor explicitly requires infection to be excluded before scoring it.

How often should SLEDAI-2K be calculated?

Typically at every rheumatology visit for active or recently changed disease, commonly every 1-3 months, with more frequent reassessment during a suspected flare or major treatment change.

Is SLEDAI-2K used in lupus nephritis specifically?

It includes renal descriptors (proteinuria, hematuria, pyuria, urinary casts) that contribute to the overall score, but dedicated renal response criteria (based on quantitative proteinuria and eGFR trends) are typically used alongside SLEDAI-2K for detailed lupus nephritis management.

What is considered a severe SLEDAI-2K score?

Commonly cited bands classify scores of 11-19 as high activity and ≥20 as very high activity, though exact cutoffs vary between cohorts. Severity is also judged by which specific high-weight descriptors (neuropsychiatric, vasculitis) are present, not the total score alone.

Does hydroxychloroquine affect the SLEDAI-2K score directly?

Hydroxychloroquine doesn't directly alter the scoring formula, but consistent use is associated with lower long-term disease activity and fewer flares, so a well-controlled patient on hydroxychloroquine will typically trend toward lower serial SLEDAI-2K scores over time.

Online Medical Tools — SLEDAI-2K

Printed on 9/3/2026

For informational purposes only. This is not medical advice.

Rheumatology

SLEDAI-2K

SLEDAI-2K (Systemic Lupus Erythematosus Disease Activity Index 2000) is a validated, weighted composite index used to quantify lupus disease activity at a point in time and track response to therapy. Twenty-four descriptors spanning neuropsychiatric, vascular, renal, musculoskeletal, mucocutaneous, serosal, immunologic, and constitutional domains are each scored present/absent within the prior 10 days (2K revision extends renal and rash descriptors to persistent findings) and summed into a single score. Rule out infection before attributing fever or cytopenias to lupus activity — cross-check with CURB-65 or SIRS if sepsis is a concern. When renal descriptors are positive, assess kidney function with eGFR and Urine Anion Gap. For inflammatory joint symptoms without other lupus features, compare against DAS28 and RA Classification Criteria to exclude concurrent RA.

Formula: Sum of weighted points (1, 2, 4, or 8) for each of 24 present descriptors within the prior 10 days.

Neuropsychiatric

Seizure (new, excl. metabolic/infectious/drug) (+8)

Psychosis (+8)

Organic Brain Syndrome (+8)

Visual Disturbance (+8)

Cranial Nerve Disorder (+8)

Lupus Headache (+8)

CVA (Stroke) (+8)

Vascular

Vasculitis (+8)

Musculoskeletal

Arthritis (≥2 joints, pain + inflammation) (+4)

Myositis (+4)

Renal

Urinary Casts (+4)

Hematuria (>5 RBC/hpf) (+4)

Proteinuria (>0.5g/24h) (+4)

Pyuria (>5 WBC/hpf) (+4)

Mucocutaneous

New Rash (+2)

Alopecia (+2)

Mucosal Ulcers (+2)

Serosal

Pleurisy (+2)

Pericarditis (+2)

Immunologic

Low Complement (C3/C4/CH50) (+2)

Increased anti-dsDNA Binding (+2)

Constitutional / Hematologic

Fever (>38°C, infection excluded) (+1)

Thrombocytopenia (<100,000/µL) (+1)

Leukopenia (<3,000/µL) (+1)

Save your results with a free account

Keep a history of calculations, favorite tools, and access your dashboard anytime.

Create free account Sign in

How It Works

Assess all 24 descriptors present within the prior 10 days

SLEDAI-2K scores 24 defined clinical and laboratory descriptors across eight organ systems, each recorded as present or absent within the 10 days preceding assessment (the 2000 revision, unlike the original SLEDAI, allows persistent proteinuria, rash, and alopecia to be scored as present even if unchanged from the prior visit, better capturing chronic active disease). Neuropsychiatric descriptors — seizure, psychosis, organic brain syndrome, visual disturbance, cranial nerve disorder, lupus headache, and CVA — each carry the highest weight (8 points) reflecting their severity and impact, as does vasculitis. Musculoskeletal and renal descriptors — arthritis, myositis, urinary casts, hematuria, proteinuria, and pyuria — are weighted 4 points each. Mucocutaneous and serosal findings — new rash, alopecia, mucosal ulcers, pleurisy, and pericarditis — plus the two immunologic markers (low complement, increased anti-dsDNA binding) are weighted 2 points each. Constitutional and hematologic findings — fever, thrombocytopenia, and leukopenia — are weighted 1 point each, reflecting their lower specificity for lupus activity versus other causes.

Exclude alternative causes before attributing a descriptor to lupus

Nearly every SLEDAI-2K descriptor requires active exclusion of a non-lupus explanation before it can be scored positive. Fever should not be scored if infection is present or more likely. Seizure should be scored only after excluding metabolic (uremia, hypoglycemia), infectious (meningitis), and drug-related causes. Cytopenias (thrombocytopenia, leukopenia) require exclusion of drug effect (especially from immunosuppressants themselves), and proteinuria attribution requires exclusion of other renal disease, medication effect, or urinary tract infection. This exclusion requirement is what makes SLEDAI-2K a clinical judgment tool rather than a simple checklist — two clinicians reviewing the same lab and imaging data can score differently if one attributes, say, thrombocytopenia to active lupus and the other to a recently started sulfonamide antibiotic. Document the reasoning for each positive descriptor, particularly for low-specificity findings like fever and cytopenias.

Sum weighted points and interpret against activity bands and flare definitions

Add the point values of every positive descriptor to obtain the total SLEDAI-2K score (theoretical maximum around 105, though real-world scores rarely exceed 45). Interpret using commonly cited bands: 0 indicates no measurable activity, 1-5 mild activity, 6-10 moderate activity, 11-19 high activity, and ≥20 very high activity — though exact band cutoffs vary somewhat between cohorts and institutions, so use them as a general guide alongside clinical judgment rather than a rigid protocol. Beyond the absolute score, SLEDAI-2K is used to define flares in longitudinal follow-up. A commonly used definition (SELENA-SLEDAI flare index) considers a flare 'mild/moderate' when the score increases by 3 or more points, or 'severe' when it increases by 12 or more points or when specific severe descriptors newly appear (e.g., new CNS lupus, vasculitis, nephritis). Track the score serially at each visit — the trend and the specific descriptors driving a change matter more for management decisions than any single absolute value.

Who Uses the SLEDAI-2K

Lupus Nephritis Flare Monitoring

Nephrologists and rheumatologists co-managing lupus nephritis

Track renal descriptors (proteinuria, hematuria, urinary casts, pyuria) alongside complement and anti-dsDNA trends at each visit to detect renal flares early, since a rising SLEDAI driven by renal descriptors often precedes a measurable creatinine rise and should prompt urgent biopsy consideration or immunosuppression escalation.

Immunosuppression Titration and Tapering

Rheumatologists managing hydroxychloroquine, mycophenolate, or belimumab regimens

Serial SLEDAI-2K scores provide the objective evidence needed to justify escalating immunosuppression during a flare or, conversely, to support a cautious steroid or immunosuppressant taper once sustained low activity is documented over multiple visits.

Clinical Trial Enrollment and Endpoint Assessment

Clinical research coordinators in lupus trials

Most modern SLE trials use SLEDAI-2K-based composite responder indices (SRI-4, BICLA) as primary endpoints, requiring precise baseline and follow-up scoring by trained assessors — this tool mirrors the calculation used in those protocols.

Neuropsychiatric Lupus Assessment

Rheumatology and neurology co-management teams

When a lupus patient develops new neurologic or psychiatric symptoms, systematically scoring the seven high-weight neuropsychiatric SLEDAI descriptors (after excluding infection, metabolic causes, and medication effects) helps determine whether CNS lupus is the likely driver and supports the case for aggressive treatment.

Distinguishing Lupus Flare From Infection in Febrile Patients

Hospitalists and rheumatology consult services

A febrile lupus patient with normal complement, no rising anti-dsDNA, and no other positive descriptors should raise suspicion for infection rather than flare — SLEDAI-2K's requirement to exclude infection before scoring fever formalizes this differential and prevents inappropriately escalating immunosuppression during an infection.

Longitudinal Disease Course Documentation

Patients and primary rheumatologists tracking chronic disease

A dated series of SLEDAI-2K scores across years of follow-up creates an objective record of disease trajectory that's far more useful for treatment decisions and specialist handoffs than subjective 'doing better/worse' notes alone.

Pro Tips

Every descriptor requires exclusion of a mimicking cause — it's not a simple checklist

Fever, cytopenias, seizure, and proteinuria all have common non-lupus explanations (infection, drug effect, other renal disease). Scoring a descriptor positive without documenting that these were considered and excluded undermines the score's validity and can lead to inappropriate immunosuppression escalation for what's actually an infection or drug reaction.

The 2000 revision allows persistent (not just new/worsening) rash, alopecia, and mucous membrane lesions

Unlike the original 1992 SLEDAI, which only counted new or recurrent findings, SLEDAI-2K scores these three mucocutaneous descriptors as present even if chronic and unchanged, better reflecting ongoing disease burden. This is a common point of confusion for clinicians trained on the older instrument.

A score of zero does not mean the patient has no lupus-related symptoms

Fatigue, Raynaud's phenomenon, and sicca symptoms — all common and burdensome lupus manifestations — are not captured by any SLEDAI-2K descriptor. A patient can have significant quality-of-life impact from lupus while scoring 0, so don't equate SLEDAI-2K score with overall disease burden or patient-reported wellbeing.

Low complement and rising anti-dsDNA can precede clinical flare by weeks

Serial immunologic monitoring (even when the clinical exam is quiet) can flag an impending flare before new organ-threatening descriptors appear, giving an opportunity for closer monitoring or early intervention rather than waiting for overt clinical deterioration.

Use the SELENA-SLEDAI flare index definitions for consistent flare classification

A mild/moderate flare is generally defined as a ≥3-point increase in SLEDAI-2K; a severe flare as a ≥12-point increase or the new appearance of a severe descriptor (new nephritis, vasculitis, CNS lupus, myositis, or platelet count <60,000). Using these standardized thresholds, rather than gestalt impression, keeps flare documentation consistent across visits and providers.

Cytopenias are weighted low (1 point) precisely because they're nonspecific

Thrombocytopenia and leukopenia in a lupus patient are frequently drug-related (from azathioprine, mycophenolate, or other agents) rather than reflecting active hematologic lupus — the low weighting reflects this, but always check a recent medication history and drug levels before attributing cytopenia to disease activity.

Renal descriptors should be interpreted alongside a formal urine protein-to-creatinine ratio, not dipstick alone

Proteinuria >0.5g/24h is the SLEDAI-2K threshold, which requires a quantitative measurement (24-hour collection or spot urine protein-to-creatinine ratio), not a qualitative dipstick reading — dipstick alone can both under- and overestimate true proteinuria.

SLEDAI-2K doesn't capture damage — pair it with SLICC/ACR Damage Index for a complete picture

SLEDAI-2K measures current, reversible disease activity, not cumulative, irreversible organ damage from past flares or treatment toxicity (e.g., avascular necrosis, chronic kidney disease, cataracts from steroids). Use the SLICC/ACR Damage Index alongside SLEDAI-2K for a full longitudinal assessment.

Common Questions About Your Results

The SLEDAI-2K fever descriptor explicitly requires that infectious causes be excluded before scoring it as lupus-related. If the infectious workup is still pending, it's reasonable to hold off on finalizing the score, or to score conservatively and revisit once results return. Documenting 'fever, infectious workup pending, SLEDAI fever descriptor deferred' is more accurate than prematurely attributing it to lupus activity, especially since treating a true infection with increased immunosuppression can be harmful.

Under the SLEDAI-2K (2000) revision, persistent proteinuria >0.5g/24h is scored as present regardless of whether it's new, worsening, or chronic and stable — this is a key difference from the original 1992 SLEDAI, which only counted new or increased proteinuria. This means a patient with quiescent but persistent proteinuria from prior nephritis damage will continue to score points on this descriptor even without active renal flare, which can make the total score appear to overstate current activity — note this in your clinical interpretation.

The descriptor is intended to capture an increase in anti-dsDNA binding, so a stable, unchanged elevated titer over multiple visits technically doesn't meet the 'increased' criterion at each subsequent visit — only score it when there's a genuine rise from the patient's own baseline or previous measurement. A chronically elevated but stable titer reflects ongoing seropositivity, not necessarily worsening activity.

Pregnancy itself can cause findings that mimic lupus activity (mild proteinuria from normal pregnancy physiology, thrombocytopenia from gestational causes, and normal complement changes), making SLEDAI-2K interpretation more challenging. Distinguishing a true flare from pregnancy-related physiologic change usually requires close collaboration with maternal-fetal medicine and may benefit from a pregnancy-adapted activity index (e.g., PGA or SLEPDAI) alongside standard SLEDAI-2K.

Inter-rater reliability is generally good for objective lab-based descriptors (complement, anti-dsDNA, quantified proteinuria) but weaker for descriptors requiring clinical judgment about exclusion of mimics (fever, cytopenias, arthritis versus non-inflammatory joint pain). When scores diverge, review which specific descriptors differ and why — usually it traces to a difference in whether an alternative cause was considered sufficiently excluded, which is a documentation and communication issue rather than a flaw in the instrument itself.

Clinical Content Trust

Last reviewed:: April 21, 2026
Guideline version:: General evidence framework v2026.04
Source set version:: Primary-source set v1

How to Interpret Your Result

SLEDAI-2K scores are commonly grouped as: 0 no activity, 1-5 mild activity, 6-10 moderate activity, 11-19 high activity, and ≥20 very high activity. A rise of ≥3 points from a prior visit indicates a mild/moderate flare, and ≥12 points (or a new severe descriptor) indicates a severe flare.

When to Use This Tool

Use SLEDAI-2K at rheumatology follow-up visits for patients with an established SLE diagnosis to quantify current disease activity, detect flares, and guide immunosuppression titration or tapering decisions.

Limitations

Every descriptor requires exclusion of non-lupus mimics (infection, drug effect, other organ disease), introducing inter-rater variability. The instrument doesn't capture fatigue, Raynaud's, sicca symptoms, or cumulative organ damage, and a score of 0 doesn't mean the patient is symptom-free.

For related assessments, see DAS28 Score, RA Classification (ACR/EULAR) and eGFR Calculator.

Disclaimer: This tool is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about your health.

Changelog

April 21, 2026 · trust-baseline
Clinical trust metadata enabled for this tool page with structured review/version fields.

Related Tools